# CCA Cancer Care AI OS — V12.2-PC1.5 Structural Conformance Phase 3

## Objective

Continue Register-driven remediation on the golden systemic-treatment pathway without changing the already-validated core for unrelated features and without inventing CCA clinical content.

## Fresh executable validation

| Gate | Result |
|---|---:|
| Defect-remediation reproductions | 38 PASS / 0 FAIL |
| V12 process + IPD | 48 PASS / 0 FAIL |
| Legacy regression | 95 PASS / 0 FAIL |
| Supplied scenario pack | 41 / 41 PASS |
| Scenario preflight | 0 failures |
| Scenario audit chain | 0 errors |
| PC1 pre-clinician | 15 PASS / 0 FAIL |
| PC1.1 UX | 9 PASS / 0 FAIL |
| PC1.2 Mature Oncology UX | 19 PASS / 0 FAIL |
| PC1.3 Track-B Phase 1 | 27 PASS / 0 FAIL |
| PC1.4 Track-B Phase 2 | 38 PASS / 0 FAIL |
| **PC1.5 Track-B Phase 3** | **58 PASS / 0 FAIL** |
| Python compile | PASS |
| Frontend JS syntax (`app`, `pc1` … `pc1_5`) | PASS |

The demo database was reset between suites and reset again after the final run.

## Major Phase-3 additions

1. Governed formulary-backed current medication with route/dose-unit/provenance controls.
2. Readiness provenance, freshness, monitoring status and signed clinician rationale.
3. Three-block systemic order sequence with governed route/diluent/rate/rounding and signed decision rationale.
4. Pharmacy verification snapshot plus server-owned preparation handling, derived BUD/final concentration, wastage controls and independent final check.
5. MAR controls for structured access, actual dose/rate units, independent chairside verification, variance reasons, post-treatment units and cumulative actual administered dose.

## Register mapping

The evidence edition `CCA_Clinical_Data_Ownership_Input_Register_v1_1_TrackB_Phase3.xlsx` contains the row-level mapping. Evidence was added only where an executable/static test supports the claim.

## Important architecture decision

`ORD-028 Final concentration` should not be copied from Pharmacy back into a signed prescriber order merely to satisfy a spreadsheet. PC1.5 calculates `PHM-016 Actual prepared concentration` during preparation. CCA Medical Oncology + Pharmacy should decide whether the order needs a distinct conditional field named **Ordered/target concentration**.

## Release interpretation

This build has zero observed failures across the listed executable suites. It is still a pre-clinician, synthetic-data product-test release. It is not evidence of institutional clinical-content approval, clinical validation, production readiness or regulatory readiness.
